复星国际上市17年来累计分红港币256亿元，分红率逐渐提升，近五年分红率在20%及以上。截至报告期末，调整后NAV为每股港币17.4元。On August 28, Fosun International (00656) announced the results for the first half of 2024. During the reporting period, the Group's revenue continued to grow, with total revenue reaching RMB 97.84 billion.
The Zhitong Finance App learned that on August 28, Fosun International (00656) announced the results for the first half of 2024. During the reporting period, the Group's revenue continued to grow, with total revenue reaching RMB 97.84 billion; the operating profit of the industry continued to grow, reaching RMB 3.47 billion. The four core subsidiaries — Yuyuan Co., Ltd., Fosun Pharmaceuticals, Fosun Portugal Insurance, and Fosun Travel & Communications — had total revenue of RMB 72.17 billion, which continued to grow year on year, accounting for 74% of the Group's total revenue.
As of the end of the reporting period, the Group's adjusted total debt to total capital ratio was 50.2%, maintaining the downward trend since 2020. Cash, bank balances and term deposits reached RMB 109.55 billion, an increase of approximately RMB 17.1 billion over the end of 2023. The international rating agency S&P fully acknowledged the results of Fosun's financial strategy and confirmed that the rating outlook is “stable.”
Fosun International has accumulated dividends of HK$25.6 billion in the 17 years since its listing. The dividend rate has gradually increased. In the past five years, the dividend rate has been 20% or more. As of the end of the reporting period, the adjusted NAV was HK$17.4 per share.
High-quality global business has become Fosun's new growth engine. By the end of the reporting period, Fosun had an industrial layout in more than 35 countries and regions around the world. In the first half of 2024, overseas revenue reached RMB 45.87 billion, an increase of 4% over the previous year, and its share of total revenue rose to 47%.
In the first half of 2024, Fosun Kechuang invested RMB 3.5 billion and made breakthrough progress in innovative drug research and development. A total of 4 products were approved for marketing with a total of 9 indications, 4 products entered the pre-marketing approval/key clinical stage, and 9 products (calculated based on indications) were approved for clinical trials.